Kris MG - Search Results

1

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Yu HA, et al. Among authors: kris mg. J Thorac Oncol. 2015 Mar;10(3):431-7. doi: 10.1097/JTO.0000000000000432. J Thorac Oncol. 2015. PMID: 25415430 Free PMC article.

2

A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer.

Rosenstein M, Armstrong J, Kris M, Shank B, Scher H, Fass D, Harrison L, Fuks Z, Leibel S. Rosenstein M, et al. Int J Radiat Oncol Biol Phys. 1992;24(1):43-8. doi: 10.1016/0360-3016(92)91019-j. Int J Radiat Oncol Biol Phys. 1992. PMID: 1324901 Clinical Trial.

3

Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.

Rusch VW, Reuter VE, Kris MG, Kurie J, Miller WH Jr, Nanus DM, Albino AP, Dmitrovsky E. Rusch VW, et al. Among authors: kris mg. J Thorac Cardiovasc Surg. 1992 Nov;104(5):1465-9. J Thorac Cardiovasc Surg. 1992. PMID: 1331621

4

Limited small-cell lung cancer: do favorable short-term results predict ultimate outcome?

Armstrong J, Shank B, Scher H, Gaynor J, Martini N, Kutcher J, Kris M. Armstrong J, et al. Am J Clin Oncol. 1991 Aug;14(4):285-90. Am J Clin Oncol. 1991. PMID: 1650527

5

Limited small cell lung cancer: prognostic significance of a complete response to the induction phase of chemotherapy followed by thoracic irradiation.

Armstrong JG, Rosenstein MM, Scher HI, Fass DE, Zelefsky MJ, Kris MG. Armstrong JG, et al. Among authors: kris mg. Radiology. 1991 Mar;178(3):875-8. doi: 10.1148/radiology.178.3.1847240. Radiology. 1991. PMID: 1847240 Clinical Trial.

6

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.

Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KM, Venkatraman ES, Woolley K, Heelan RT, Kris MG. Miller VA, et al. Among authors: kris mg. Cancer. 1995 Feb 15;75(4):968-72. doi: 10.1002/1097-0142(19950215)75:4<968::aid-cncr2820750411>3.0.co;2-y. Cancer. 1995. PMID: 7842417 Clinical Trial.

7

Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.

Cleri LB, Kris MG, Tyson LB, Pisters KM, Clark RA, Gralla RJ. Cleri LB, et al. Among authors: kris mg. Cancer. 1995 Sep 1;76(5):774-8. doi: 10.1002/1097-0142(19950901)76:5<774::aid-cncr2820760510>3.0.co;2-5. Cancer. 1995. PMID: 8625179 Clinical Trial.

8

The role of multimodality therapy in locoregional non-small cell lung cancer.

Martini N, Kris MG, Ginsberg RJ. Martini N, et al. Among authors: kris mg. Surg Oncol Clin N Am. 1997 Oct;6(4):769-91. Surg Oncol Clin N Am. 1997. PMID: 9309093 Review.

9

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.

Kindler HL, Kris MG, Smith IE, Miller VA, Grant SC, Krebs JB, Ross GA, Slevin ML. Kindler HL, et al. Among authors: kris mg. Am J Clin Oncol. 1998 Oct;21(5):438-41. doi: 10.1097/00000421-199810000-00003. Am J Clin Oncol. 1998. PMID: 9781595 Clinical Trial.

10

Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer.

Martini N, Rusch VW, Bains MS, Kris MG, Downey RJ, Flehinger BJ, Ginsberg RJ. Martini N, et al. Among authors: kris mg. J Thorac Cardiovasc Surg. 1999 Jan;117(1):32-6; discussion 37-8. doi: 10.1016/s0022-5223(99)70467-8. J Thorac Cardiovasc Surg. 1999. PMID: 9869756 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

523 results

Search Page

Filters